Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07674771 · ClinicalTrials.gov registry record · Early Phase 1
Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery
A Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT07674771: Clinical Trial Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
NCT07674771 is a Early Phase 1 study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 30 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07674771, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the reduction in PSMA-avid tumor volume and metastasis-directed radiotherapy treatment intensity facilitated by PET PSMA-response adapted SABR for poly-metastatic castration sensitive prostate cancer.
Primary Outcome
will be measured by the decrease in TTV (%) on a per-patient basis between the initial scan and post-SABR PSMA PET.
Interventions
- DRUG 68Ga-PSMA-11
- DRUG Drug: 68-Ga PSMA11
- RADIATION Adaptive stereotactic ablative radiotherapy (SABR)
- RADIATION Adaptive stereotactive ablative radiotherapy (SABR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2029-06-15 |
| Phase | Early Phase 1 |
What is known before NCT07674771 opens enrollment
NCT07674771 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 4 interventions - of which 68Ga-PSMA-11 is the first listed.
NCT07674771 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07674771 about?
NCT07674771 is a clinical study titled "Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery". The purpose of this study is to characterize the reduction in PSMA-avid tumor volume and metastasis-directed radiotherapy treatment intensity facilitated by PET PSMA-response adapted SABR for poly-metastatic castration sensitive prostate cancer.
What is the current status of trial NCT07674771?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2026-07-15. Estimated completion is 2029-06-15.
What interventions are being tested in trial NCT07674771?
The interventions under investigation include: 68Ga-PSMA-11 (DRUG), Drug: 68-Ga PSMA11 (DRUG), Adaptive stereotactic ablative radiotherapy (SABR) (RADIATION), Adaptive stereotactive ablative radiotherapy (SABR) (RADIATION).
Who is sponsoring clinical trial NCT07674771?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07674771's enrollment target sits among peer trials
30 807th of 2000 higher than 1,074 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI